2200 N. Commerce Parkway
Weston, FL 33326
754 231 1688
Full Time Employees: 6
|Mr. Stephen C. Glover||Co-Founder, Chairman, CEO & Pres||450.5k||N/A||1960|
|Mr. Peter Wolfe||CFO & Sec.||275k||N/A||1968|
|Mr. Nicholas A. LaBella Jr., MS, RPh.||Chief Scientific Officer and Sr. VP of R&D||325k||N/A||1956|
|Ms. Karen A. Cashmere||Chief Commercial Officer||300k||N/A||1952|
|Ms. Melda Uzbil O'connell||Sr. VP of Corp. Devel.||N/A||N/A||N/A|
|Dr. Pablo A. Guzman FACC, M.D.||Chief Medical Officer, Sr. VP of Medical Affairs & Chairman of Renal Scientific Advisory Board||N/A||N/A||1950|
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
ZyVersa Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.